Wave Life Sciences (WVE) Reports Q2 Loss, Misses Revenue Estimates

Company Performance - Wave Life Sciences reported a quarterly loss of $0.31 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.29, and compared to a loss of $0.25 per share a year ago, indicating a negative earnings surprise of -6.90% [1] - The company posted revenues of $8.7 million for the quarter ended June 2025, missing the Zacks Consensus Estimate by 31.16%, and down from $19.69 million in the same quarter last year [2] - Over the last four quarters, Wave Life Sciences has surpassed consensus EPS estimates only once and has also topped consensus revenue estimates just once [2] Stock Performance - Wave Life Sciences shares have declined approximately 32.7% since the beginning of the year, contrasting with the S&P 500's gain of 8.3% [3] - The current Zacks Rank for Wave Life Sciences is 4 (Sell), indicating expectations of underperformance in the near future [6] Future Outlook - The consensus EPS estimate for the upcoming quarter is -$0.29 on revenues of $14.5 million, and for the current fiscal year, it is -$1.12 on revenues of $49.27 million [7] - The outlook for the Medical - Biomedical and Genetics industry, where Wave Life Sciences operates, is currently in the top 37% of over 250 Zacks industries, suggesting a favorable industry environment [8]